Assessment by quantitative ultrasonometry of the effects of hormone replacement therapy on bone mass

2000 ◽  
Vol 182 (3) ◽  
pp. 529-534 ◽  
Author(s):  
Peyman Hadji ◽  
Olaf Hars ◽  
Mathias Schüler ◽  
Karin Bock ◽  
Christian Wüster ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Bone Mass ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Quantitative Ultrasonometry

scholarly journals Effect of hormone replacement therapy on the bone mass and urinary excretion of pyridinium cross-links

2000 ◽  
Vol 118 (1) ◽  
pp. 3-6 ◽  
Author(s):  
Dolores Perovano Pardini ◽  
Anibal Tagliaferri Sabino ◽  
Ana Maria Meneses ◽  
Teresa Kasamatsu ◽  
José Gilberto Henriques Vieira
Keyword(s):  
Hormone Replacement Therapy ◽  
Bone Resorption ◽  
Bone Mass ◽  
Urinary Excretion ◽  
Replacement Therapy ◽  
High Performance ◽  
Hormone Replacement ◽  
Mineral Density ◽  
Cross Links ◽  
Post Menopausal

CONTEXT: The menopause accelerates bone loss and is associated with an increased bone turnover. Bone formation may be evaluated by several biochemical markers. However, the establishment of an accurate marker for bone resorption has been more difficult to achieve. OBJECTIVE: To study the effect of hormone replacement therapy (HRT) on bone mass and on the markers of bone resorption: urinary excretion of pyridinoline and deoxypyridinoline. DESIGN: Cohort correlational study. SETTING: Academic referral center. SAMPLE: 53 post-menopausal women, aged 48-58 years. MAIN MEASUREMENTS: Urinary pyr and d-pyr were measured in fasting urine samples by spectrofluorometry after high performance liquid chromatography and corrected for creatinine excretion measured before treatment and after 1, 2, 4 and 12 months. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry (DEXA) before treatment and after 12 months of HRT. RESULTS: The BMD after HRT was about 4.7% (P < 0.0004); 2% (P < 0.002); and 3% (P < 0.01) higher than the basal values in lumbar spine, neck and trochanter respectively. There were no significant correlations between pyridinium cross-links and age, weight, menopause duration and BMD. The decrease in pyr and d-pyr was progressive after HRT, reaching 28.9% (P < 0.0002), and 42% (P < 0.0002) respectively after 1 year. CONCLUSIONS: Urinary pyridinoline and deoxypyridinoline excretion decreases early in hormone replacement therapy, reflecting a decrease in the bone resorption rate, and no correlation was observed with the bone mass evaluated by densitometry.

P171 Serum lipids and bone mass density before and after hormone replacement therapy

Maturitas ◽  
1996 ◽  
Vol 27 ◽  
pp. 170
Author(s):  
J. Paver ◽  
M Borovský ◽  
J Murín ◽  
Z Killinger ◽  
P Ondrejka
Keyword(s):  
Hormone Replacement Therapy ◽  
Bone Mass ◽  
Replacement Therapy ◽  
Serum Lipids ◽  
Mass Density ◽  
Hormone Replacement ◽  
Bone Mass Density ◽  
Before And After

Hormone replacement therapy improves distal radius bone structure by endocortical mineral deposition

2003 ◽  
Vol 81 (10) ◽  
pp. 952-958 ◽  
Author(s):  
Monique E Muller ◽  
Colin E Webber ◽  
Jonathan D Adachi
Keyword(s):  
Computed Tomography ◽  
Hormone Replacement Therapy ◽  
Bone Mass ◽  
Trabecular Bone ◽  
Replacement Therapy ◽  
Distal Radius ◽  
Bone Structure ◽  
Hormone Replacement ◽  
Rapid Loss ◽  
Hole Area

Hormone replacement therapy (HRT) produces a small increase in bone mineral density (BMD) when measured by dual energy X-ray absorptiometry (DXA). The corresponding decrease in fracture risk is more impressive, implying that other factors that contribute to bone strength are favourably modified by HRT. We investigated, using peripheral quantitated computed tomography (pQCT), the changes produced by HRT in both the distribution of mineral between cortical and trabecular bone and the changes produced by HRT in the apparent structure of trabecular bone, expressed as average hole area and apparent connectivity. Twenty-one postmenopausal women starting HRT and 32 control women were followed for 2 years, with distal radius pQCT measurements every 6 months. HRT prevented the loss of total bone mass seen in controls (p < 0.02). HRT also produced an apparent rapid loss of trabecular bone mass within the first 6 months of the study (p < 0.02), with an associated rapid loss in the apparent connectivity (p = 0.034). Average hole area also increased but not to a statistically significant extent. Exogenous estrogen apparently fills small marrow pores close to the endocortical surface, such that the pQCT-defined boundary between trabecular and cortical bone is shifted in favour of cortical bone. Trabecular bone structure indices are adversely affected, as the central, poorly interconnected trabecular bone with greater than average marrow spaces constitutes a greater fraction of the remaining trabecular bone. This study suggests that the improvements in fracture risk resulting from HRT are explained by a reversal of net endocortical resorption of bone.Key words: average hole area, connectivity, distal radius, endocortical resorption, hormone replacement therapy, peripheral quantitated computed tomography, trabecular structure.

scholarly journals Hormone Replacement Therapy Associated White Blood Cell DNA Methylation and Gene Expression are Associated With Within-Pair Differences of Body Adiposity and Bone Mass

2015 ◽  
Vol 18 (6) ◽  
pp. 647-661 ◽  
Author(s):  
Aileen Bahl ◽  
Eija Pöllänen ◽  
Khadeeja Ismail ◽  
Sarianna Sipilä ◽  
Tuija M. Mikkola ◽  
...  
Keyword(s):  
Gene Expression ◽  
Dna Methylation ◽  
Body Composition ◽  
Hormone Replacement Therapy ◽  
Bone Mass ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Differentially Expressed ◽  
Body Adiposity ◽  
Genome Wide

The loss of estrogen during menopause causes changes in the female body, with wide-ranging effects on health. Estrogen-containing hormone replacement therapy (HRT) leads to a relief of typical menopausal symptoms, benefits bone and muscle health, and is associated with tissue-specific gene expression profiles. As gene expression is controlled by epigenetic factors (including DNA methylation), many of which are environmentally sensitive, it is plausible that at least part of the HRT-associated gene expression is due to changes in DNA methylation profile. We investigated genome-wide DNA methylation and gene expression patterns of white blood cells (WBCs) and their associations with body composition, including muscle and bone measures of monozygotic (MZ) female twin pairs discordant for HRT. We identified 7,855 nominally significant differentially methylated regions (DMRs) associated with 4,044 genes. Of the genes with DMRs, five (ACBA1, CCL5, FASLG, PPP2R2B, and UHRF1) were also differentially expressed. All have been previously associated with HRT or estrogenic regulation, but not with HRT-associated DNA methylation. All five genes were associated with bone mineral content (BMC), and ABCA1, FASLG, and UHRF1 were also associated with body adiposity. Our study is the first to show that HRT associates with genome-wide DNA methylation alterations in WBCs. Moreover, we show that five differentially expressed genes with DMRs associate with clinical measures, including body fat percentage, lean body mass, bone mass, and blood lipids. Our results indicate that at least part of the known beneficial HRT effects on body composition and bone mass may be regulated by DNA methylation associated alterations in gene expression in circulating WBCs.

Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major

2003 ◽  
Vol 74 (1) ◽  
pp. 68-71 ◽  
Author(s):  
E. Carmina ◽  
G. Di Fede ◽  
N. Napoli ◽  
G. Renda ◽  
G. Vitale ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Bone Mass ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Thalassemia Major ◽  
Adult Women
Sign in / Sign up

Export Citation Format

Share Document